Rosiglitazone Versus Theophylline in Asthmatic Smokers
Status:
Completed
Trial end date:
2007-06-01
Target enrollment:
Participant gender:
Summary
Asthmatic smokers display a blunted response to both inhaled and oral corticosteroid
treatments and are at increased risk for exacerbations and near fatal asthma. The prevalence
of smoking in asthmatics runs between 20-30%. Therefore, new, more efficacious treatments are
required.
Recent work has demonstrated a mechanism which may explain steroid resistance. A commonly
used drug called theophylline can reverse this steroid resistance in laboratory studies.
Another commonly used drug, rosiglitazone can reverse smoking induced lung inflammation in
laboratory studies.
The investigators aim to study the effects of these drugs on smoking asthmatics' lung
function and other parameters including quality of life and asthma control.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
University of Glasgow
Collaborators:
Chest, Heart and Stroke Association Scotland Chief Scientist Office of the Scottish Government GlaxoSmithKline